Patient selection guidelines and DUE for drotecogin alfa (activated)

Formulary

Volumn 37, Issue SUPPL. 1, 2002, Pages 3-15

  Applebaum, Steven ^a   Carter, Charles ^a   Chuen, Thomas ^a   Dedrick, Steve ^a   Dunsworth, Greg ^a   Edwards, William ^a   Fish, Doug ^a   Hodgman, Tudy ^a   Huntress, Jeff ^a   Jacobi, Judith ^a   Koemer, Pamela ^a   Komfuhrer, Harold ^a   Kuhl, David ^a   Mann, Henry ^a   Martin, Steve ^a   Mosko, Paul ^a   Rihn, Thomas ^a   Rudis, Maria ^a   Shane, Rita ^a   Vanscoy, Gordon ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; DROTRECOGIN; PLACEBO; RECOMBINANT PROTEIN;

CLINICAL TRIAL; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; HEALTH CARE COST; HUMAN; MORBIDITY; MORTALITY; PATIENT SELECTION; PRACTICE GUIDELINE; REVIEW; SEPSIS; SYNDROME;

EID: 0036226477     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Teamwork used to be a money saver; now it's a lifesaver
2. Epidemiology of sepsis syndrome in 8 academic medical centers
3. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs
4. Definitions for sepsis and multiple organ failure, and guidelines for the use of innovative therapies in sepsis
5. Efficacy and safety of recombinant human activated protein C for severe sepsis
6. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2
7. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction
8. Recombinant human activated protein C, drotrecogin alfa (activated); A novel therapy for severe sepsis